Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236853 | 1.00 | PIK3CA (0.33) | PIK3CAPIK3R1NR1H2ALOX5APFEN1 | |
| SCHEMBL24936208 | 0.81 | CHEK1 (0.43) | NR1H2GPR119 | |
| SCHEMBL25674626 | 0.79 | GPR119 (0.37) | PIK3CAPIK3R1NR1H2GPR119 | |
| SCHEMBL31022739 | 0.79 | NR1H2 (0.34) | PIK3CAPIK3R1NR1H2PIK3CDPIK3CB | |
| SCHEMBL25285467 | 0.79 | NR1H2 (0.34) | PIK3CAPIK3R1NR1H2PIK3CDPIK3CB | |
| SCHEMBL24936205 | 0.76 | CHEK1 (0.44) | NR1H2ALOX5APFEN1 | |
| SCHEMBL25674630 | 0.75 | PIK3R1 (0.36) | PIK3CAPIK3R1NR1H2PIK3CDPIK3CB | |
| SCHEMBL25235364 | 0.75 | GPR119 (0.34) | PIK3CAPIK3R1NR1H2PIK3CDPIK3CB | |
| SCHEMBL31022733 | 0.73 | PIK3R1 (0.31) | PIK3CAPIK3R1NR1H2GPR119 | |
| SCHEMBL25674623 | 0.73 | PIK3R1 (0.31) | PIK3CAPIK3R1NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129049-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-24 | — | — | US | disclosed |
| EP-4455134-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | Sumitomo Pharma Co., Ltd. (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-118434726-A | 1H-pyrazol-3-amine derivatives having a bicyclic skeleton | 住友制药株式会社 | 2024-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129049-A1 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | CHEK1, BUB1B, CHEK2 | PIK3CA 1045/4885PIK3R1 480/4885NR1H2 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.